PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer
| Autor: | Rebecca L. Lewis, Kristen L Miller |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
medicine.medical_specialty medicine.medical_treatment media_common.quotation_subject Programmed Cell Death 1 Receptor Immune system Programmed cell death 1 Health care medicine Humans In patient Neoplasm Metastasis Intensive care medicine General Environmental Science media_common biology Squamous Cell Carcinoma of Head and Neck business.industry Head and neck cancer Immunotherapy medicine.disease Discontinuation Head and Neck Neoplasms biology.protein General Earth and Planetary Sciences business |
| Zdroj: | Clinical Journal of Oncology Nursing. 23:627-638 |
| ISSN: | 1538-067X 1092-1095 |
| DOI: | 10.1188/19.cjon.627-638 |
| Popis: | Background Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with programmed cell death protein 1 (PD-1) inhibitors has been associated with risk of developing immune-mediated adverse reactions (IMARs). Objectives This review provides nurses with an overview of the safety of PD-1 inhibitors approved by the U.S. Food and Drug Administration for recurrent or metastatic SCCHN following platinum chemotherapy, as well as recommendations for assisting with the diagnosis and management of IMARs. Methods PubMed® searches were conducted to identify relevant articles to support this review. Algorithms from drug manufacturers for IMAR management were also reviewed. Findings Before treatment with PD-1 inhibitors, nurses should map patients' baseline profiles, which play a key role in aiding the healthcare team in the timely diagnosis and treatment of IMARs. Nurses should educate patients and caregivers on identifying signs and symptoms of IMARs and their progression. Within the interprofessional healthcare team, nurses play an important role in ensuring efficient management of IMARs to minimize withholding or discontinuation of PD-1 immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|